Skip to content Provide accessibility feedback
For Providers
For Patients
Customer Stories
About Us
Contact Us
Magnifying glass Search

Volpara has entered into a Scheme Implementation Agreement with Lunit, Inc.

Clinically validated, AI-powered software for personalized screening and early detection of breast cancer.

Map of clinics using Volpara in the US


Facilities use Volpara Health software for early detection of breast cancer, including top US cancer screening centers.



Mammography technologists rely on Volpara Health to improve mammogram quality.

Volpara gives us confidence that we did the best possible job for our patients.

– Deborah Hamel, Quality Assurance Manager, Derry Imaging


16.5 m+

Women across 40 countries have had their breast density assessed by Volpara Health.

Knowing precisely how dense my breasts are gave me a clear path for screening.

– Patient, Reno Diagnostic Centers

100 m+

Mammography and tomosynthesis images have been deidentified and analyzed by Volpara Health.

Every image we evaluate helps us evolve and improve our software, creating a path toward a healthier future.

– Lester Litchfield, Head of Data Science, Volpara Health

Trusted by Healthcare Leaders

Get ready for 2024

January 1, 2024

New NAPBC Standards

The new NAPBC Standards Manual (2024) is a shift to more personalized care delivery with greater use of risk assessment and preventative protocols.

September 10, 2024

New FDA Density Rule

The Food & Drug Administration has updated the Mammography Quality Standards Act (MQSA) to make patient breast density notification a federal requirement.

What's New

Explore events, resources and viewpoints.


NCoBC 2024

24 Oct 2023

AI that Works in Breast Imaging: Volpara literally wrote the eBook!

27 Jun 2023

Volpara is Microsoft’s 2023 Healthcare & Life Sciences Partner of the Year

FDA national breast density notification requirement